Niagen Bioscience
CompanyUnited States
Niagen Bioscience develops 8 assets, the furthest in phase 1 (Niagen in fatigue). Mostly supplement and small molecule acting on NAD+ metabolism, sirtuin signalling and Mitochondrial biogenesis (PGC-1α); based in the United States.
- 8
- Assets
- Furthest stage
- Phase 1
- 0
- Trials
- 13
- Signals
Pipeline
8Nicotinamide riboside acts as an NAD+ precursor to increase NAD+ levels.
Phase 1, Supplement, Mitochondrial biogenesis (PGC-1α), Sirtuin signalling, fatigue, pharmacokinetic
Boosts NAD+ levels to support cellular health.
Human trials, Supplement, long COVID
Nicotinamide riboside-derived small molecule boosting NAD+ levels
Preclinical, Small molecule, NAD+ metabolism, ataxia telangiectasia
5 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Deals9
- People13
- Signals20
- Similar companies6